Alethio Therapeutics

Executive Summary

Alethio Therapeutics is a private UK-based biotechnology company focused on developing disease-modifying biologic therapies for chronic blood cancers, specifically myeloproliferative neoplasms (MPNs). Founded in 2019 and headquartered in Cambridge, the company leverages its proprietary ARTEMIS discovery and development engine to create antibody-drug conjugates (ADCs) and other biologics that selectively target disease-driving cells. By combining deep scientific expertise with a precision approach, Alethio aims to transform outcomes for patients with MPNs, a group of disorders characterized by overproduction of blood cells and limited treatment options. The company operates at the intersection of antibody engineering and targeted therapy, positioning itself as a potential leader in the MPN space. Alethio's pipeline remains in early preclinical stages, with no publicly disclosed lead candidates or clinical programs. The company's near-term focus is likely on advancing its ADC platform, identifying lead candidates, and progressing toward investigational new drug (IND)-enabling studies. With a strong scientific foundation and a clear unmet need in MPNs, Alethio is well-positioned to attract further investment and partnerships. However, given its early stage and lack of clinical data, significant risks remain, including technical challenges in ADC development and competition from established players. The company's success will hinge on its ability to demonstrate preclinical proof-of-concept and move efficiently into the clinic.

Upcoming Catalysts (preview)

• Q4 2026Lead Candidate Nomination for ADC Program60% success
• Q2 2027Completion of IND-Enabling Studies for Lead Candidate50% success
• Q3 2026Partnership or Series A/B Financing Announcement40% success